be purchased in order to perform such function(s).

Part IV of the proposed order provides that, for up to 120 days after service of the order, respondent may continue to ship products from existing stock in packaging with nonconforming labeling, as long as the packaging was printed less than 30 days after the date respondent signed the consent agreement.

Parts VI through IX require Palm to keep copies of relevant advertisements and materials substantiating claims made in the advertisements, to provide copies of the order to certain of its personnel, to notify the Commission of changes in corporate structure, and to file compliance reports with the Commission. Part X provides that the order will terminate after twenty (20) years under certain circumstances.

The purpose of this analysis is to facilitate public comment on the proposed order, and it is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 02–5968 Filed 3–12–02; 8:45 am]

**BILLING CODE 6750–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the National Human Research Protections Advisory Committee (NHRPAC)

**AGENCY:** Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science, Office for Human Research Protections.

**ACTION:** Notice of meeting.

**SUMMARY:** Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Human Research Protections Advisory Committee (NHRPAC).

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person listed below. Individuals planning on attending the meeting and who want to ask questions must submit their requests in writing in advance of the meeting to the contact person listed below.

**DATES:** The Committee will hold its next meeting on April 29–30, 2002. The meeting will convene EST from 8:30 a.m. to its recess at approximately 5:30 p.m. on April 29 and resume at 8:30 a.m. to 5 p.m. on April 30.

**ADDRESSES:** Hyatt Regency Bethesda Hotel, One Bethesda Metro, Bethesda, MD, (301) 657–1234.

**FOR FURTHER INFORMATION CONTACT:** Keisha Johnson, Program Assistant, National Human Research Protections Advisory Committee, Office for Human Research Protections, The Tower Building, 1101 Wootton Parkway, Suite 200, Rockville, Maryland 20852, (301) 435–4917. The electronic mail address is: *kjohnson@osophs.dhhs.gov.*

**SUPPLEMENTARY INFORMATION:** The National Human Research Protections Advisory Committee was established on June 6, 2000, to provide expert advice and recommendations to the Secretary of HHS, Assistant Secretary for Health, the Director, Office for Human Research Protections, and other departmental officials on a broad range of issues and topics pertaining to or associated with the protection of human research subjects.

Information about NHRPAC, and the draft agenda for the Committee's April 2002 meeting, will be posted on the NHRPAC website at: *http://ohrp.osophs.dhhs.gov/nhrpac/nhrpac.htm.*

Dated: March 7, 2002.

**Greg Koski,**

*Executive Secretary, National Human Research Protections Advisory Committee.*

[FR Doc. 02–5925 Filed 3–12–02; 8:45 am]

**BILLING CODE 4150–28–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 01N–0437]**

### Agency Information Collection Activities; Submission for OMB Review; Comment Request; New Animal Drugs for Investigational Use; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of January 14, 2002 (67 FR 1772). The document announced that a proposed collection of information had been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. The document was published with an incorrect OMB control number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Doris Tucker, Office of Policy, Planning, and Legislation (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7010.

**SUPPLEMENTARY INFORMATION:** In FR Doc. 02–855, appearing on page 1772 in the **Federal Register** of Monday, January 14, 2002, the following correction is made:

1. On page 1772, in the second column, in the fourteenth line, ''0910–0017'' is corrected to read ''0910–0117''.

Dated: March 5, 2002.

**Margaret M. Dotzel,**

*Associate Commissioner for Policy.*

[FR Doc. 02–5922 Filed 3–12–02; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 02D–0073]**

### ''Guidance for Industry: Validation of Procedures for Processing of Human Tissues Intended for Transplantation;'' Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled ''Guidance for Industry: Validation of Procedures for Processing of Human Tissues Intended for Transplantation'' dated March 2002. The guidance document is intended to remind all tissue establishments that the current requirement to prepare, validate, and follow procedures to prevent infectious disease contamination or cross-contamination during the processing of human tissues intended for transplantation includes such infectious disease agents as viruses, bacteria, fungi, and will include transmissible spongiform encephalopathy (TSE)-associated prions as technology progresses.

**DATES:** General comments on agency guidance documents are welcome at any time. The agency is soliciting public comment, but is implementing this guidance document immediately because of public health concerns. FDA is requesting that you submit with your comments any information on specific methods currently used by tissue establishments to prevent infectious disease contamination and cross-